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A case-control pilot study was conducted using existing banked bone marrow specimens from the Children's Oncology Group (COG) AAML0531 group-wide phase III study. AAML0531 was a COG phase III, randomized, controlled trial that investigated the use of gemtuzumab ozogamicin (GMTZ) combined with conventional therapy for de novo AML in patients between the ages of 1 month and 30 years. The pilot study protocol was not considered as research on human subjects and was exempt from review by the IRB at The Children's Hospital of Philadelphia. Study participants with available bone marrow specimens at the end of Induction I or II were eligible for inclusion. Only white patients without Trisomy 21 were included. Bone marrow samples showing tumor cell contamination or which did not meet RNA Acute myeloid leukemia (AML) is the second most common leukemia in childhood, requiring one of the most intensive chemotherapeutic regimens used in pediatric oncology. While long-term cure rates have improved with the use of intensive chemotherapy, infection is a significant source of morbidity and mortality for pediatric AML patients [1] [2] [3] . Viridans group streptococcal (VGS) bloodstream infection (BSI) and invasive fungal infection (IFI) are major causes of morbidity and mortality in pediatric AML [1, [4] [5] [6] . Genome-wide expression profiling reflects the dynamic influence of environment on transcriptional activity, and has led to the identification of characteristic expression 'signatures' of various infectious agents in actively infected patients [7] [8] [9] . We investigated the novel application of expression profiling to identify increased host susceptibility to VGS BSI and IFI, hypothesizing that identification of differential constitutional expression of immune pathways prior to the occur-quality standards were excluded. VGS cases were defined as patients who developed their first VGS BSI after bone marrow specimen procurement, during Induction or Intensification cycles. IFI cases were defined as patients with microbiological evidence of fungal infection from sterile sites and were identified similarly to VGS cases. Controls were defined as patients who developed neither VGS BSI nor IFI during Induction or Intensification phases. Bone marrow specimens were shipped overnight at room temperature to the AML reference laboratory to maximize viability. Total RNA was isolated using Qiagen RNeasy ® . Microarray services were provided by the Robust multiple-array average normalization was applied, and unsupervised analysis was performed using principal components analysis. Class comparison between cases and controls was then performed using one-way ANOVA, with multiple testing correction. Eighteen VGS cases, 8 IFI cases and 22 controls met the inclusion and exclusion criteria and were included for microarray processing and analysis. The 18 VGS cases represented a total of 32 episodes of VGS bacteremia. There was one IFI event for each IFI case. Five of 8 IFI cases also had VGS infection during the study period. Fifty percent of VGS cases, 50% of IFI cases and 65% of controls were males (p = 0.46). The median age at diagnosis of the VGS cases, IFI cases and control group was 7.7, 13.4 and 10.4 years, respectively (p = 0.49). All bone marrow specimens from controls and IFI cases were obtained at the end of Induction I. Sixteen of 18 VGS case specimens were obtained at the end of Induction I and the other 2 were obtained at the end of Induction II (p = 0.29). Median RNA concentration in the cases and controls differed significantly (p = 0.01), with VGS and IFI cases having lower median RNA concentrations than the controls. Median 260: 280 in cases and controls did not differ significantly (p = 0.33). Principal components analysis did not reveal significant differences among the 3 groups. Class comparison using one-way ANOVA did not reveal genes with a >1.5-fold difference in expression between groups, and no gene expression patterns were found to be predictive of the development of VGS or IFI events.
In this case-control pilot study, we were unable to show any significant differences in preinfection gene expression that would allow the prediction of VGS or IFI events. This study had several limitations that may have contributed to the negative result. Delays inherent in shipment of bone marrow samples and resulting suboptimal storage conditions prior to arrival at the COG AML laboratory may have resulted in degraded RNA transcripts that confounded the study results [10] . The diverse cell type population within the bone marrow could create significant background signals to mask any meaningful expression pattern produced by a specific cell lineage comprising a minority of the cell population. Future work may benefit from sorting according to cell type to allow comparison of gene expression profiles within homogeneous cell populations. Lastly, the small number of subjects meeting study inclusion criteria resulted in limited statistical power and ability to control for potential confounders.
In summary, we performed genome-wide expression analysis of bone marrow specimens from subjects with pediatric AML to identify a gene expression profile predictive of the development of VGS and IFI complications during chemotherapy. We were unable to distinguish any differences in expression patterns between cases and controls. Further studies are needed to establish the potential for gene expression profiling as a predictive tool for infectious outcomes in pediatric AML patients.
